Platelets prevent the development of monocrotaline-induced liver injury in mice.


Journal

Toxicology letters
ISSN: 1879-3169
Titre abrégé: Toxicol Lett
Pays: Netherlands
ID NLM: 7709027

Informations de publication

Date de publication:
15 Dec 2020
Historique:
received: 01 07 2020
revised: 05 10 2020
accepted: 16 10 2020
pubmed: 31 10 2020
medline: 29 12 2020
entrez: 30 10 2020
Statut: ppublish

Résumé

Destruction of liver sinusoidal endothelial cells (LSECs) is an initial event in sinusoidal obstruction syndrome (SOS) that leads to accumulation of platelets in the liver. Herein, we explored the role of platelets during progression of experimental SOS induced by monocrotaline (MCT) in mice. Depletion of platelets using an anti-CD41 antibody or anti-thrombocyte serum exacerbated MCT-induced liver injury in C57BL/6 mice, as indicated by an increase in the alanine transaminase (ALT) level, which was associated with hemorrhagic necrosis. Thrombocytosis induced by thrombopoietin (TPO) or the TPO receptor agonist romiplostim (ROM) attenuated MCT-induced liver injury, as evidenced by lower levels of ALT and mRNA encoding matrix metalloproteinase (MMP) 9, and higher levels of mRNA encoding vascular endothelial growth factor receptor (VEGFR) 2 and VEGFR3. The level of activated hepatic platelets was higher in TPO- and ROM-treated mice than in saline-treated mice. Co-culture with a high number of platelets increased the viability of LSECs and their mRNA levels of CD31, VEGFR2, and VEGFR3, and decreased their mRNA level of MMP9. The level of VEGF-A was increased in the culture medium of LSECs co-cultured with platelets. These results indicate that platelets attenuate MCT-induced liver injury by minimizing damage to LSECs.

Identifiants

pubmed: 33122006
pii: S0378-4274(20)30444-6
doi: 10.1016/j.toxlet.2020.10.007
pii:
doi:

Substances chimiques

Receptors, Fc 0
Receptors, Thrombopoietin 0
Recombinant Fusion Proteins 0
Monocrotaline 73077K8HYV
Thrombopoietin 9014-42-0
romiplostim GN5XU2DXKV

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

71-81

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflicts of interest to disclose.

Auteurs

Fumisato Otaka (F)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan; Departments of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan; Departments of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Yoshiya Ito (Y)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan; Departments of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan. Electronic address: yito@kitasto-u.ac.jp.

Takuya Goto (T)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan.

Koji Eshima (K)

Departments of Immunology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Hideki Amano (H)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan; Departments of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Wasaburo Koizumi (W)

Departments of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Masataka Majima (M)

Department of Molecular Pharmacology, Graduate School of Medical Sciences, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan; Departments of Pharmacology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan; Department of Medical Therapeutics, Kanagawa Institute of Technology, Atsugi, Kanagawa 243-0292, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH